Zuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies
Juliana Almeida Oliveira, Karine Eskandar, Marcos Aurélio Araújo Freitas, Chris Elizabeth Philip · 2024
Read Zuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies by Juliana Almeida Oliveira, Karine Eskandar, Marcos Aurélio Araújo Freitas, Chris Elizabeth Philip (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11637452.txt.
Description
Juliana Almeida Oliveira and three co-authors review a drug for postpartum depression in a 2024 paper. The drug, zuranolone, is the first pill approved for this condition. It offers care outside a hospital, which matters for new mothers. The team asked how well it works and how safe it is.
The authors searched three large databases in September 2023. They kept only trials that compared the drug with a placebo. Two trials with 346 women met the rules for the review. The drug raised response and remission rates at several time points. It also cut the need for other antidepressant doses. Sleepiness was the main added risk and grew with dose. The authors call the drug promising but say safety needs more study.
Catalog record
| CREATOR | Juliana Almeida Oliveira, Karine Eskandar, Marcos Aurélio Araújo Freitas, Chris Elizabeth Philip |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |